Literature DB >> 20681993

The relationship between reduced testosterone, stimulated growth hormone secretion and increased carotid intima-media thickness in obese men.

Hideo Makimura1, Takara L Stanley, Noelle Sun, Jean M Connelly, Linda C Hemphill, Steven K Grinspoon.   

Abstract

OBJECTIVE: Obesity is associated with reduced testosterone and growth hormone (GH). However, the interrelationship between these axes and their independent contributions to cardiovascular risk is unknown. The objectives of this study were to determine (1) the association between testosterone and GH in obesity, (2) whether excess adiposity mediates this association and (3) the relative contribution of reduced testosterone and GH to increased carotid intima-media thickness (cIMT) in obesity.
DESIGN: Fifty obese men were studied with GH-releasing hormone-arginine testing, and morning free testosterone (FT) was measured by equilibrium dialysis. Metabolic, anthropometric and cardiovascular risk indices, including cIMT were measured. Twenty-six normal weight men served as controls.
RESULTS: Obese subjects demonstrated lower mean (±SEM) peak stimulated GH (5·9 ± 0·6 vs 36·4 ± 3·9 μg/l; P < 0·0001) and FT (0·41 ± 0·03 vs 0·56 ± 0·03 nmol/l; P = 0·0005) compared to controls. GH was significantly associated with FT (r = +0·44; P < 0·0001) and both were inversely related to visceral adipose tissue (VAT) (GH: r = -0·65; P < 0·0001; FT: r = -0·51; P < 0·0001). In multivariate regression analysis controlling for VAT, FT was no longer related to GH. Both GH and FT were associated with cIMT in univariate analysis. However, in multivariate modelling including traditional cardiovascular risk markers, GH (β = 0·003; P = 0·04) but not FT (P = 0·35) was associated with cIMT.
CONCLUSIONS: These results demonstrate a strong relationship between FT and GH in obesity and suggest that this relationship is more a function of excess adiposity rather than a direct relationship. While reduced FT and GH are both related to increased cIMT, the relationship with reduced GH remains significant controlling for reduced FT and traditional cardiovascular disease risk markers.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20681993      PMCID: PMC3225917          DOI: 10.1111/j.1365-2265.2010.03859.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  32 in total

1.  Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels.

Authors:  J C Seidell; P Björntorp; L Sjöström; H Kvist; R Sannerstedt
Journal:  Metabolism       Date:  1990-09       Impact factor: 8.694

2.  Impaired growth hormone response to growth hormone releasing factor and insulin-hypoglycaemia in obesity.

Authors:  P G Kopelman; K Noonan; R Goulton; A J Forrest
Journal:  Clin Endocrinol (Oxf)       Date:  1985-07       Impact factor: 3.478

3.  Pathogenesis of the decreased androgen levels in obese men.

Authors:  V A Giagulli; J M Kaufman; A Vermeulen
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

4.  Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction.

Authors:  T Williams; M Berelowitz; S N Joffe; M O Thorner; J Rivier; W Vale; L A Frohman
Journal:  N Engl J Med       Date:  1984-11-29       Impact factor: 91.245

5.  Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men.

Authors:  A Iranmanesh; G Lizarralde; J D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  1991-11       Impact factor: 5.958

6.  Testosterone administration increases insulin-like growth factor-I levels in normal men.

Authors:  C J Hobbs; S R Plymate; C J Rosen; R A Adler
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

Review 7.  The role of sexual steroids in the modulation of growth hormone (GH) secretion in humans.

Authors:  J Devesa; N Lois; V Arce; M J Diaz; L Lima; J A Tresguerres
Journal:  J Steroid Biochem Mol Biol       Date:  1991       Impact factor: 4.292

8.  The relative contribution of androgens and insulin in determining abdominal body fat distribution in premenopausal women.

Authors:  R Pasquali; F Casimirri; V Balestra; R Flamia; N Melchionda; R Fabbri; L Barbara
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

9.  The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys.

Authors:  G Marin; H M Domené; K M Barnes; B J Blackwell; F G Cassorla; G B Cutler
Journal:  J Clin Endocrinol Metab       Date:  1994-08       Impact factor: 5.958

10.  Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.

Authors:  F Cordido; F F Casanueva; C Dieguez
Journal:  J Clin Endocrinol Metab       Date:  1989-02       Impact factor: 5.958

View more
  1 in total

1.  Testosterone and cardiac mass and function in men with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications Study (EDIC).

Authors:  Catherine Kim; Ionut Bebu; Barbara Braffett; Patricia A Cleary; Valerie Arends; Michael Steffes; Hunter Wessells; Trevor Orchard; Aruna V Sarma
Journal:  Clin Endocrinol (Oxf)       Date:  2016-01-25       Impact factor: 3.478

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.